Skip to main content
Supriya Lifescience Limited logo

Supriya Lifescience Limited — Investor Relations & Filings

Ticker · SUPRIYA ISIN · INE07RO01027 LEI · 894500RBVJX1EOJP0Y02 BSE.NS Manufacturing
Open in API
Filings indexed 468 across all filing types
Latest filing 2023-05-26 Board/Management Inform…
Country IN India
Listing BSE.NS SUPRIYA

About Supriya Lifescience Limited

https://www.supriyalifescience.com

Supriya Lifescience Limited is a research-driven manufacturer of Active Pharmaceutical Ingredients (APIs) with a focus on diverse therapeutic segments. The company specializes in the production of antihistamines, anti-allergics, vitamins, anesthetics, and anti-asthmatics. Its core product portfolio includes Chlorpheniramine Maleate, Ketamine Hydrochloride, and Salbutamol Sulphate, maintaining a significant global market share in these niche categories. Operating with a strong emphasis on backward integration, the firm ensures supply chain reliability and cost efficiency. The manufacturing infrastructure is compliant with international regulatory standards, including approvals from the USFDA, EDQM, and PMDA. Supriya Lifescience serves a broad international clientele across more than 100 countries, catering to both regulated and semi-regulated markets through its advanced R&D capabilities and commitment to quality excellence.

Recent filings

Filing Released Lang Actions
Appointment
Board/Management Information Classification · 100% confidence The document is an official communication addressed to stock exchanges (BSE and NSE) regarding the appointment of a new director, Mr. Balasaheb Sawant, as an Additional Director and Whole Time Director. It references compliance with SEBI Listing Regulations and provides details about the appointment, including the term and qualifications of the appointee. There is no financial data, earnings information, or report publication mentioned. The content clearly relates to a change in the company's board of directors and senior management. Therefore, the document fits the category of Board/Management Information (MANG). The document length is 4504 characters, which is consistent with a detailed announcement rather than a brief notice or report publication announcement.
2023-05-26 English
Resignation
Board/Management Information Classification · 100% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) informing about the resignation of a Whole Time Director and Key Managerial Personnel, Mr. Manoj Dorlikar, effective May 26, 2023. It references compliance with Regulation 30 of SEBI Listing Obligations and Disclosure Requirements, which pertains to disclosure of events or information about changes in the company's board or management. The content is focused on management change and includes details about the resignation, but does not contain financial data, audit information, or other report types. The document length is 3310 characters, which is relatively short and consistent with a management change announcement rather than a full report. Therefore, the appropriate classification is Board/Management Information (MANG).
2023-05-26 English
Updates
Regulatory Filings
2023-05-26 English
Dividend Updates
Regulatory Filings
2023-05-26 English
Press Release
Board/Management Information Classification · 95% confidence The document is a press release announcing the appointment of Dr. Shekhar Bhirud as President – Business Development, Strategy and R&D, designated as Key Managerial Personnel of Supriya Lifescience Limited. It is addressed to stock exchanges and references SEBI Listing Regulations, indicating a regulatory announcement. The content focuses on management appointment details, qualifications, and statements from company leadership. There are no financial statements, earnings data, or detailed financial analysis present. The document is not a full annual or interim report, nor is it a call transcript or governance report. It clearly announces a change in senior management. Therefore, the document fits the category of Board/Management Information (MANG). The document length (6676 characters) supports it being a full announcement rather than a brief notice or report publication announcement. Confidence is high given the clear subject and content.
2023-05-26 English
Financial Result Updates
Regulatory Filings
2023-05-26 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.